TTR and neuropathy: Following the switch from inotersen to eplontersen, there was further reduction in mean serum TTR levels (− 80.6%) at Week 85, which was consistent with the reduction seen for eplontersen treatment in the NEURO-TTRansform trial at Week 85 (− 81.8%) [19], and apparent benefit towards neuropathy impairment, QoL, nutritional status, and overall safety and tolerability, including restoration of platelet count to baseline levels.